Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

is trial. Efficacy evaluations will include the measure of target lesions (per RECIST), and the quantization of symptom relief. Further details of this trial can be found at http://www.clinicaltrials.gov.

The other five sites currently participating in this Phase II trial are: 1) the Hematology Oncology Services of Arkansas in Little Rock, Arkansas, 2) the Dana-Farber Cancer Institute in Boston, MA. 3) Mount Sinai in New York City, 4) Lahey Clinic in Burlington, MA. and 5) Scott & White Memorial Hospital in Temple TX.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Callisto earlier announced in June, 2006 interim data from a Phase I trial of Atiprimod in advanced cancer patients. The patients who were entered into this trial had growing tumors and symptoms that were no longer controlled by the standard therapies utilized. During treatment, three of the five advanced carcinoid patients had measurable tumor regressions and loss of many of the debilitating symptoms of this disease.

About Carcinoid Cancer

Carcinoid tumors, or carcinoids, originate in hormone-producing cells of the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer are diag
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... our ability to target experimental cancer treatments ... hand, and more are on the way ... drugs, MILAN, Italy, April 27 , At today,s ... Meeting,of the European Association for the Study of the Liver ...
... Virology Translate Into New Promising Drugs to Combat Hepatitis ... ... Stem Cells of Potential Benefit in Liver ... Liver Diseases, At today,s sessions of the 43rd Annual Meeting of the European,Association ...
Cached Medicine Technology:Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC) 2Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC) 3Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/11/2014)... WA (PRWEB) July 11, 2014 College ... within one week of injury, but developed recurrent instability ... at the American Orthopaedic Society for Sports Medicine’s ( ... guide team physicians in providing the most optimal treatment ... who suffered an anterior shoulder instability event, and found ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... education regarding modifiable risk factors may minimize the chance ... suggests that a few risk factors such as, age, ... to the possibility of re-injury," said lead author, Christopher ...
(Date:7/11/2014)... Bethpage, NY (PRWEB) July 11, 2014 Wild ... Kullen, is proud to announce they are opening a fifth ... , Wild by Nature offers one of the largest selections ... of people diagnosed with celiac disease, these stores have become ... a gluten-free diet. , Gluten sensitivity, and gluten intolerance, is ...
(Date:7/11/2014)... BellasDress, the experienced dressmaker in the ... suppliers when it comes to beach wedding dresses ... of beach wedding outfits in its online shop. Included ... outfits. , BellasDress has been considered as one ... to the company’s senior spokesman, BellasDress provides superb special ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Growing old was thought ... then. However, in recent studies, it was shown that many of ... credence behind them. As it turns out, the elderly can still ... , Of course, with all the time in the world, older ... them to indulge their passions in the twilight of their lives. ...
Breaking Medicine News(10 mins):Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:Wild by Nature Opens New Location 2Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:It’s All Free For Seniors Review, How To Take Advantage of What Life Has to Offer In Old Age – Vinamy.com 2Health News:It’s All Free For Seniors Review, How To Take Advantage of What Life Has to Offer In Old Age – Vinamy.com 3
... of a recent study researchers say Lipid-lowering drugs can be ... at a follow-up appointment with a doctor. ,Researchers ... during a hospital stay vs. in an outpatient setting and ... States and Canada were involved in the study, 175 patients ...
... known scientist and accomplished businessman of the U.S. holding ... to set up a high end rapid //diagnostic centre ... be a marketing, selling and research company. ... BioAsia 2004 conference Bangalore on February 28, he said ...
... findings researchers say the risks and benefits of using ... Researchers from Sweden studied more than 3,000 men who ... had their intellectual capacity tested at age 18 years ... for the young men. ,Results of the study ...
... use of hormone replacement therapy among breast cancer survivors has ... rate of recurring or new cancers. ,Swedish researchers embarked ... the disease and therefore subject to the same menopausal symptoms ... 1,300 women over five years. After the initial 345 women ...
... serious consequence of osteoporosis. Such a break can lead to ... ,According to a recent study , it was found ... to be effective in reducing the risk for a vertebral ... the drug can reduce the risk of breaking a bone ...
... reprogram their brains to improve motor skills, say researchers ... ,Functional magnetic resonance imaging and a "cyberglove" record ... redirect motor commands. Stroke or traumatic brain injury results ... until now, scientists were not sure which neurons compensated ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: